Bio-Technology General's Bio-Tropin (somatropin) hGH clears FDA, will reach market in August.
Executive Summary
BIO-TECHNOLOGY GENERAL BIO-TROPIN SHOULD BE AVAILABLE IN AUGUST following the May 25 approval of the recombinant human growth hormone product for treatment of children of short stature with hGH deficiency. Bio-Tropin will be the fourth version of somatropin to be approved after Lilly's Humatrope, Genentech's Nutropin, and Novo Nordisk's recently approved Norditropin ("The Pink Sheet" May 15, p. 6). Genentech's hGH product Protropin (somatrem) differs by one amino acid from the somatropin products.